Verschraegen C

ORCID: 0000-0001-6544-3089 · 1 paper in corpus

2015

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Journal of Clinical Oncology ·doi:10.1200/jco.2015.61.6490

PurposeProgesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II study. This multicenter, prospective, randomized, placebo-contr…